Anti-Amyloid Immunotherapy Comparison

📖 Wiki Page

therapeutic1086 wordssynced 2026-04-02

Anti-Amyloid Immunotherapy Comparison

Overview

flowchart TD Anti_Amyloid_Immunotherapy_Com["Anti-Amyloid Immunotherapy Comparison"] Anti_Amyloid_Immunotherapy_Com["Anti-Amyloid"] Anti_Amyloid_Immunotherapy_Com -->|"related to"| Anti_Amyloid_Immunotherapy_Com style Anti_Amyloid_Immunotherapy_Com fill:#81c784,stroke:#333,color:#000 Anti_Amyloid_Immunotherapy_Com["table"] Anti_Amyloid_Immunotherapy_Com -->|"related to"| Anti_Amyloid_Immunotherapy_Com style Anti_Amyloid_Immunotherapy_Com fill:#81c784,stroke:#333,color:#000 Anti_Amyloid_Immunotherapy_Com["class"] Anti_Amyloid_Immunotherapy_Com -->|"related to"| Anti_Amyloid_Immunotherapy_Com style Anti_Amyloid_Immunotherapy_Com fill:#81c784,stroke:#333,color:#000 style Anti_Amyloid_Immunotherapy_Com fill:#4fc3f7,stroke:#333,color:#000

...

Anti-Amyloid Immunotherapy Comparison

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Anti-Amyloid Immunotherapy Comparison</th>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Abeta protofibrils</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>N-terminal truncated Abeta</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Conformational epitopes</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>Aggregated Abeta</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>Oligomers and plaques</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>FDA Status</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Full approval</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Full approval</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>Withdrawn</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>Not approved</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>Not approved</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>ARIA-E Rate (Treatment)</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>12.6%</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>24.0%</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>35.5%</td>
</tr>
<tr>
<td class="label">Gantenerumab</td>
<td>25.0%</td>
</tr>
<tr>
<td class="label">Crenezumab</td>
<td>6.5%</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>ARIA-H Rate (Treatment)</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>17.3%</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>31.4%</td>
</tr>
<tr>
<td class="label">Aducanumab</td>
<td>19.1%</td>
</tr>
<tr>
<td class="label">Endpoint</td>
<td>Description</td>
</tr>
<tr>
<td class="label">CDR-SB</td>
<td>Clinical Dementia Rating Sum of Boxes</td>
</tr>
<tr>
<td class="label">iADRS</td>
<td>Integrated Alzheimer's Disease Rating Scale</td>
</tr>
<tr>
<td class="label">ADAS-Cog</td>
<td>Alzheimer's Disease Assessment Scale-Cognitive</td>
</tr>
<tr>
<td class="label">MMSE</td>
<td>Mini-Mental State Examination</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>What It Measures</td>
</tr>
<tr>
<td class="label">Amyloid PET (SUVr)</td>
<td>Amyloid plaque burden</td>
</tr>
<tr>
<td class="label">CSF p-tau181</td>
<td>Tau pathology</td>
</tr>
<tr>
<td class="label">FDG-PET</td>
<td>Brain glucose metabolism</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Lecanemab</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Protofibrils</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>10 mg/kg q2w</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>CLARITY-AD</td>
</tr>
<tr>
<td class="label">CDR-SB benefit</td>
<td>-0.45</td>
</tr>
<tr>
<td class="label">ARIA-E rate</td>
<td>12.6%</td>
</tr>
<tr>
<td class="label">FDA status</td>
<td>Approved</td>
</tr>
<tr>
<td class="label">Plaque removal</td>
<td>59 centiloids</td>
</tr>
</table>

Anti-amyloid immunotherapies represent the first disease-modifying treatments for Alzheimer's disease, targeting the accumulation of amyloid-beta (Abeta) plaques in the brain. This comparison matrix provides a comprehensive analysis of the major monoclonal antibody therapies that have reached late-stage clinical development, examining their mechanisms of action, clinical trial results, safety profiles, and practical considerations for clinical use.

Mechanism of Action Comparison

Monoclonal Antibodies vs Small Molecules

All FDA-approved anti-amyloid immunotherapies are monoclonal antibodies administered intravenously. They differ in their specific targets:

Target Specificity

The different targets reflect distinct hypotheses about the most toxic form of Aβ:

Plaque-targeting: Gantenerumab, Donanemab
Oligomer-targeting: Crenezumab, Aducanumab
Protofibril-targeting: Lecanemab

Protofibrils are soluble, highly toxic Aβ aggregates that are believed to be the most pathogenic species. Lecanemab's focus on protofibrils may explain its favorable efficacy profile[@van2023].

Phase 3 Clinical Trial Results

Lecanemab (Leqembi)

Trial: CLARITY-AD (Phase 3)
Population: Early AD (MCI due to AD or mild AD dementia)
Primary endpoint: CDR-SB change at 18 months
Results: -0.45 vs placebo (p<0.001), 27% slowing of decline
Amyloid reduction: 59 centiloids at 18 months
FDA status: Full approval (January 2023)

Donanemab (Kisunla)

Trial: TRAILBLAZER-ALZ 2 (Phase 3)
Population: Early AD with low-medium tau
Primary endpoint: iADRS change at 24 months
Results: -4.2 vs placebo (p<0.001), 35% slowing in low-medium tau
Amyloid reduction: Complete plaque removal in 52% of patients
FDA status: Full approval (July 2024)

Aducanumab (Aduhelm)

Trials: EMERGE (positive), ENGAGE (negative)
Population: Early AD
Primary endpoint: CDR-SB change at 78 weeks
Results: EMERGE: -0.22 vs placebo (p=0.012); ENGAGE: not significant
FDA status: Withdrawn from market (2024)
Note: Accelerated approval withdrawn by manufacturer

Gantenerumab

Trial: GRADUATE-1/2 (Phase 3)
Population: Early AD
Results: Did not meet primary endpoint (negative)
Status: Development discontinued

Crenezumab

Trial: CREAD (Phase 3)
Population: Early AD
Results: Did not meet primary endpoint (negative)
Status: Development discontinued

SAR228810

Trial: Phase 2
Status: Development discontinued

FDA Status Summary

ARIA Incidence Rates

Amyloid-related imaging abnormalities (ARIA) are the major safety concern with anti-amyloid immunotherapies:

ARIA-E (Edema)

ARIA-H (Hemorrhage)

ARIA Management

Monitoring: MRI at baseline, 5th dose, 7th dose, and as symptoms develop
Symptom management: Hold dosing if symptomatic ARIA detected
Risk factors: APOE ε4 carrier status, anticoagulation use

Dosing Protocols

Lecanemab (Leqembi)

Dose: 10 mg/kg every 2 weeks
Infusion time: Approximately 1 hour
Premedication: Not required
Dosing adjustments: None recommended

Donanemab (Kisunla)

Dose: 350 mg every 4 weeks (after titration)
Titration: 350 mg at weeks 0, 2, 4; then 1400 mg at week 8
Infusion time: Approximately 30 minutes
Dosing pause: Can be discontinued after achieving amyloid clearance

Efficacy Endpoints

Clinical Measures

Biomarker Measures

Patient Selection Criteria

Appropriate Patients

Diagnosis: MCI due to AD or mild AD dementia
Amyloid confirmation: Positive amyloid PET or CSF biomarker
Tau staging: Low-medium tau for optimal response
Age: Typically 50-85 years
MMSE: Usually ≥20

Contraindications

Anticoagulation: P2Y12 inhibitors, warfarin with INR>3
Prior ARIA: History of ARIA with previous anti-amyloid therapy
Active infection: Significant CNS infection
Unstable medical conditions

Comparison Matrix Table

*iADRS endpoint

Cross-Linked Pages

[diseases/alzheimers-disease] - Alzheimer's Disease
[diseases/mci] - Mild Cognitive Impairment
[biomarkers/amyloid-pet] - Amyloid PET
[biomarkers/csf-biomarkers] - CSF Biomarkers
[clinical-trials/clarity-ad] - CLARITY-AD Trial
[clinical-trials/trailblazer-alz] - TRAILBLAZER-ALZ Trial

Summary

Anti-amyloid immunotherapies represent a paradigm shift in Alzheimer's disease treatment. Lecanemab and Donanemab have demonstrated clinically meaningful benefits in early AD, though both require careful patient selection and monitoring for ARIA. The field continues to evolve with combination approaches and next-generation therapies in development.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)

[Sims JR, Zimmer JA, Evans CD, et al., Donanemab in Early Symptomatic Alzheimer's Disease. JAMA. 2023;330(6):512-527 (2023)](https://doi.org/10.1001/jama.2023.13239)

[Budd Haeberlein S, Aisen PS, Barkhof F, et al., Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. J Prev Alzheimers Dis. 2022;9(2):197-210 (2022)](https://doi.org/10.14283/jpad.2022.30)

Unknown, Alzforum. Clinical Trials Database (n.d.)

📖 View canonical wiki page →

Anti-Amyloid Immunotherapy Comparison

Anti-Amyloid Immunotherapy Comparison

Overview

Anti-Amyloid Immunotherapy Comparison

Overview

Mechanism of Action Comparison

Monoclonal Antibodies vs Small Molecules

Target Specificity

Phase 3 Clinical Trial Results

Lecanemab (Leqembi)

Donanemab (Kisunla)

Aducanumab (Aduhelm)

Gantenerumab

Crenezumab

SAR228810

FDA Status Summary

ARIA Incidence Rates

ARIA-E (Edema)

ARIA-H (Hemorrhage)

ARIA Management

Dosing Protocols

Lecanemab (Leqembi)

Donanemab (Kisunla)

Efficacy Endpoints

Clinical Measures

Biomarker Measures

Patient Selection Criteria

Appropriate Patients

Contraindications

Comparison Matrix Table

Cross-Linked Pages

Summary

See Also

External Links

References